NCT01937832 is a Phase 3 clinical trial of Faropenem in Community Acquired Pneumonia, sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd..

Who is sponsoring NCT01937832?

NCT01937832 is sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd..

What drugs are being tested in NCT01937832?

Interventions in NCT01937832: Faropenem, Ertapenem.

What condition does NCT01937832 study?

NCT01937832 studies Community Acquired Pneumonia.

Is NCT01937832 still recruiting?

NCT01937832 is currently status unknown. Last updated 4 September 2013.

Last reviewed 2013-09-04 · How we verify

NCT01937832

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Phase III Study to Evaluate the Efficacy and Safety of Faropenem in the Treatment of Adult Community-acquired Bacterial Pneumonia

Status unknown Phase 3 Last updated 4 September 2013

What this trial tests

Phase 3 trial testing Faropenem in Community Acquired Pneumonia in 540 participants. Status unknown.

Timeline

1 October 2013

Primary endpoint
1 October 2015

Quick facts

Lead sponsor	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase	Phase 3
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	540
Start date	1 October 2013
Primary completion	1 October 2015
Sites	7 locations across China

Drugs / interventions tested

Faropenem (FAROPENEM) — full drug profile →
Ertapenem (ERTAPENEM) — full drug profile →

Conditions studied

Community Acquired Pneumonia — all drugs for Community Acquired Pneumonia →

Sponsor

Chia Tai Tianqing Pharmaceutical Group Co., Ltd. — full company profile →

Who can join

Adults 18 to 73, any sex, with Community Acquired Pneumonia. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Per subject clinical cure rate
Time frame: 7-14 days

Sponsor's own description

The purpose of this study is to evaluate the safety and Efficacy of Faropenem in community-acquired pneumonia (CAP) subjects

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Innovative Strategies in Drug Repurposing to Tackle Intracellular Bacterial Pathogens.
Lorente-Torres B, Llano-Verdeja J, Castañera P, Ferrero HÁ, et al · · 2024 · cited 6× · PMID 39335008 · DOI 10.3390/antibiotics13090834

Verify or expand the search:

Other trials of Faropenem

Trials testing the same drug.

NCT06804096 — Efficacy and Safety of Faropenem in Bangladeshi Adult Patients With Community-Acquired Bacterial Pneumonia (CABP) · Phase 4 · recruiting
NCT02381470 — Trial of Faropenem and Cefadroxil (in Combination With Amoxicillin/Clavulanic Acid and Standard TB Drugs) in Patients Wi · Phase 2 · completed

Other recruiting trials for Community Acquired Pneumonia

Currently open trials in the same condition.

NCT06986148 — Comparing Antibiotic Treatment Strategies for Children With Pneumonia in Outpatient Settings: (STAMPP) · NA · recruiting

Other Chia Tai Tianqing Pharmaceutical Group Co., Ltd. trials

Trials by the same sponsor.

NCT06990776 — A Clinical Trial to Evaluate the Efficacy and Safety of TQA3605 Tablets in Treatment-naive Chronic HBV-infected Subjects · Phase 2 · withdrawn
NCT06851442 — Clinical Trial of Evaluating TQB3912 Tablets Combined With Fulvestrant Injection±TQB3616 Capsules for Locally Advanced o · Phase 1, PHASE2 · terminated
NCT06711991 — A Clinical Trial of TQC3927 Powder for Inhalation in Chronic Obstructive Pulmonary Disease · Phase 1 · completed
NCT06672276 — To Evaluate the Pharmacokinetics and Safety of TQD3606 for Injection in Subjects With Renal Insufficiency · Phase 1 · completed
NCT06644417 — Clinical Study of TQA3605 Tablets Combined With Nucleoside (Acid) Analogs (NAs) Drugs Compared With NAs Drugs in the Tre · Phase 2 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01937832 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Last refreshed: 4 September 2013

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01937832.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing